• Webster Equity Partners agreed to acquire Lifecore Biomedical for USD 6.28 a share in cash at closing.
• Deal value up to USD 663.7 million, assuming full achievement of performance milestones tied to contingent value rights.
• Each share also gets one non-tradable CVR, with up to USD 160 million in aggregate cash payouts.
• Total potential consideration up to USD 9.67 per common share equivalent if all milestones are met.
• Closing targeted for end of Q4 2026; shares expected to be delisted from Nasdaq upon completion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280845PRIMZONEFULLFEED9834696) on September 28, 2026, and is solely responsible for the information contained therein.